Baxter International Inc. and Tel Aviv University (TAU) through Ramot have entered a new licensing agreement that will be assessing technologies that are being developed at the university and Tel Aviv Sourasky Medical Center (TASMC).
The agreement will facilitate the relationship between Baxter, TAU and TASMC, as they create innovative surgical care options.
"By working with leading experts at TAU and TASMC, we have access to promising early-stage research that could have a meaningful impact for surgeons looking for new tools to treat complex cases," Wil Boren, president of Advanced Surgery at Baxter, said.
Baxter will license one agreement for the TAU Technology Innovation Momentum Fund; the second agreement will be with TAU and TASMC for joint research activity applications.
"We are gratified to see another one of TAU’s technologies graduating from our unique value enhancement program the TAU Technology Innovation Momentum Fund,” Ramot CEO Shlomo Nimrodi said.
Through their relationship, the three organizations are excited about focusing on unmet needs, which will also help Baxter increase their product portfolio.